CXCR4 and chronic myelogenous leukemia, BCR-ABL1 positive: These findings support the hypothesis in which miR-181a, MIF, and CXCR4 may contribute to immune dysregulation in CML as well as diagnostic biomarkers and promising therapeutic target.